Morgan Stanley raised the firm’s price target on CG Oncology (CGON) to $79 from $56 and keeps an Overweight rating on the shares. The approval of Inlexzo and higher-than-expected price bolsters Morgan Stanley’s confidence in creto’s regulatory pathway ahead as well as peak sales potential, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Buy Rating for CG Oncology: Creto’s Market Potential and Strategic Pricing Flexibility
- CG Oncology Highlights Drug Potential at Healthcare Conference
- CG Oncology initiated with a Buy at JonesResearch
- Buy Rating for CG Oncology: Promising NMIBC Treatment and Strong Financial Position